# Re-evaluating the Duration in Children of TB Treatment

> **NCT07656012** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 230 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT07656012
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656012, "Re-evaluating the Duration in Children of TB Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07656012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*